Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hologic ( (HOLX) ) has provided an announcement.
On April 7, 2026, Hologic completed its acquisition by funds managed by Blackstone and TPG in a transaction valued at up to $79 per share, turning the women’s health specialist into a privately held company with minority backing from ADIA and GIC. Hologic shareholders are set to receive $76 in cash plus a non‑tradable contingent value right tied to revenue milestones in the Breast Health business, while its Nasdaq-listed common stock has ceased trading and will be delisted, leaving the company a wholly owned subsidiary of the buyout consortium.
The merger triggered a comprehensive reshaping of Hologic’s capital structure, governance and incentives, including cash and CVR-based treatment of options and stock awards and the cancellation of high-strike options with no payout. Longtime chief executive Stephen MacMillan resigned with closing, with veteran medtech executive José (Joe) E. Almeida appointed CEO and sole director, signaling an intensified private equity-backed push to accelerate growth and innovation in women’s health technologies.
The most recent analyst rating on (HOLX) stock is a Buy with a $83.00 price target. To see the full list of analyst forecasts on Hologic stock, see the HOLX Stock Forecast page.
Spark’s Take on HOLX Stock
According to Spark, TipRanks’ AI Analyst, HOLX is a Neutral.
The score is driven primarily by strong cash flow and a stable balance sheet, partially offset by a sharp TTM revenue decline and margin compression. Technicals are mildly supportive with price holding above key moving averages, while valuation is less compelling at ~23x earnings with no dividend yield provided.
To see Spark’s full report on HOLX stock, click here.
More about Hologic
Hologic, Inc. is a global medical technology company focused on women’s health, developing products that detect, diagnose and treat conditions to raise standards of care worldwide. The company is particularly known for its breast health technologies and other diagnostic and interventional solutions serving healthcare providers and female patients globally.
Average Trading Volume: 4,487,897
Technical Sentiment Signal: Buy
Current Market Cap: $16.97B
Learn more about HOLX stock on TipRanks’ Stock Analysis page.